$-0.01 EPS Expected for Orgenesis Inc. (ORGS)

June 14, 2018 - By Peter Erickson

Orgenesis Inc. (NASDAQ:ORGS) Logo

Analysts expect Orgenesis Inc. (NASDAQ:ORGS) to report $-0.01 EPS on July, 16.After having $-0.52 EPS previously, Orgenesis Inc.’s analysts see -98.08 % EPS growth. It closed at $9.3 lastly. It is down 7.14% since June 14, 2017 and is downtrending. It has underperformed by 19.71% the S&P500.

Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company has market cap of $101.34 million. It operates through two divisions, Contract Development and Manufacturing Organizations and Cellular Therapy (CT) Business. It currently has negative earnings. The CDMO segment specializes in cell therapy development for advanced medicinal products.

More recent Orgenesis Inc. (NASDAQ:ORGS) news were published by: Nasdaq.com which released: “Orgenesis CDMO Partner Atvio Biotechnology’s CEO to Present on Roundtable at the 2018 BIO International Convention” on June 04, 2018. Also Globenewswire.com published the news titled: “Orgenesis and Atvio Biotechnology to Present at the World Advanced Therapies & Regenerative Medicine Congress” on May 16, 2018. Seekingalpha.com‘s news article titled: “Orgenesis, Inc. – Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline” with publication date: June 03, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: